Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;18(5):421-426.
doi: 10.2217/pgs-2017-0028. Epub 2017 Mar 27.

Institutional profile: University of Florida Health Personalized Medicine Program

Larisa H Cavallari  1   2   3 , Kristin W Weitzel  1   2   3 , Amanda R Elsey  1   3 , Xinyue Liu  4 , Scott A Mosley  1   2 , Donald M Smith  1   2 , Benjamin J Staley  4   5 , Almut G Winterstein  4   6 , Carol A Mathews  7 , Francesco Franchi  8 , Fabiana Rollini  8 , Dominick J Angiolillo  8 , Petr Starostik  9 , Michael J Clare-Salzler  3   9 , David R Nelson  2   10 , Julie A Johnson  1   2   3   10
Affiliations
Review

Institutional profile: University of Florida Health Personalized Medicine Program

Larisa H Cavallari et al. Pharmacogenomics. 2017 Apr.

Abstract

The University of Florida (UF) Health Personalized Medicine Program launched in 2012 with CYP2C19 genotyping for clopidogrel response at UF Health Shands Hospital. We have since expanded CYP2C19 genotyping to UF Health Jacksonville and established the infrastructure at UF Health to support clinical implementation for five additional gene-drug pairs: TPMT-thiopurines, IFNL3 (IL28B)-PEG IFN-α-based regimens, CYP2D6-opioids, CYP2D6/CYP2C19-antidepressants and CYP2C19-proton pump inhibitors. We are contributing to the evidence based on outcomes with genotype-guided therapy through pragmatic studies of our clinical implementations. In addition, we have developed a broad array of educational programs for providers, trainees and students that incorporate personal genotype evaluation to enhance participant learning.

Keywords: PEG-interferon; clopidogrel; education; genotype; implementation; opioids; pharmacogenetics; proton pump inhibitors; selective serotonin uptake inhibitors; thiopurines.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work was supported by the NIH grant U01 HG007269, as part of the NIH IGNITE network. Additional support provided by NIH U01 GM074492 and U01 HL105198 (both part of the NIH Pharmacogenomics Research Network), and by substantial institutional support from the University of Florida and its Clinical Translational Science Institute (UL1 TR000064 and UL1 TR001427). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Timeline of launch of pharmacogenetic implementations at University of Florida Health.
See this image and copyright information in PMC

References

    1. Johnson JA, Elsey AR, Clare-Salzler MJ, Nessl D, Conlon M, Nelson DR. Institutional Profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics. 2013;14(7):723–726. - PMC - PubMed
    1. Weitzel KW, Elsey AR, Langaee TY, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am. J. Med. Genet. C Semin. Med. Genet. 2014;166C(1):56–67. - PMC - PubMed
    1. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin. Pharmacol. Ther. 2012;92(4):437–439. - PMC - PubMed
    1. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 2012;91(2):321–326. - PMC - PubMed
    1. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 2015;98(2):127–134. - PMC - PubMed